NO320999B1 - Anordning for transdermal administrering av 2 aktive ingredienser i separate seksjoner og dens fremstillingsprosess. - Google Patents
Anordning for transdermal administrering av 2 aktive ingredienser i separate seksjoner og dens fremstillingsprosess. Download PDFInfo
- Publication number
- NO320999B1 NO320999B1 NO19985807A NO985807A NO320999B1 NO 320999 B1 NO320999 B1 NO 320999B1 NO 19985807 A NO19985807 A NO 19985807A NO 985807 A NO985807 A NO 985807A NO 320999 B1 NO320999 B1 NO 320999B1
- Authority
- NO
- Norway
- Prior art keywords
- protective film
- section
- active ingredient
- added
- matrix
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title claims description 54
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 230000001681 protective effect Effects 0.000 claims description 68
- 239000011159 matrix material Substances 0.000 claims description 52
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 38
- 239000010410 layer Substances 0.000 claims description 36
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 36
- 229950008546 trimegestone Drugs 0.000 claims description 36
- 229930182833 estradiol Natural products 0.000 claims description 32
- 229960005309 estradiol Drugs 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 21
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 20
- 239000000853 adhesive Substances 0.000 claims description 18
- 230000001070 adhesive effect Effects 0.000 claims description 18
- 239000011505 plaster Substances 0.000 claims description 16
- 239000002356 single layer Substances 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 12
- 239000000262 estrogen Substances 0.000 claims description 11
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 8
- 239000002250 absorbent Substances 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 239000002998 adhesive polymer Substances 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 229940011871 estrogen Drugs 0.000 claims description 8
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 8
- 230000000962 progestomimetic effect Effects 0.000 claims description 8
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 5
- 229960002568 ethinylestradiol Drugs 0.000 claims description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 4
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
- 229960004976 desogestrel Drugs 0.000 claims description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 2
- 229960003309 dienogest Drugs 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960005352 gestodene Drugs 0.000 claims description 2
- 229960004400 levonorgestrel Drugs 0.000 claims description 2
- 229960004616 medroxyprogesterone Drugs 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- 229960001652 norethindrone acetate Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 claims description 2
- 229950011191 norgesterone Drugs 0.000 claims description 2
- 229960000417 norgestimate Drugs 0.000 claims description 2
- 229940063238 premarin Drugs 0.000 claims description 2
- 229960001584 promegestone Drugs 0.000 claims description 2
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 9
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 5
- 230000009245 menopause Effects 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920005789 ACRONAL® acrylic binder Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- -1 diethylene glycol monoalkyl ethers Chemical class 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940100640 transdermal system Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BODMYPYTCKYRSP-UHFFFAOYSA-N 1,1-dioctylcyclohexane Chemical compound CCCCCCCCC1(CCCCCCCC)CCCCC1 BODMYPYTCKYRSP-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229920003146 methacrylic ester copolymer Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9607209A FR2749514B1 (fr) | 1996-06-11 | 1996-06-11 | Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament |
PCT/FR1997/001024 WO1997047305A1 (fr) | 1996-06-11 | 1997-06-10 | Systemes transdermiques renfermant deux principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament |
Publications (3)
Publication Number | Publication Date |
---|---|
NO985807D0 NO985807D0 (no) | 1998-12-11 |
NO985807L NO985807L (no) | 1999-02-10 |
NO320999B1 true NO320999B1 (no) | 2006-02-27 |
Family
ID=9492920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19985807A NO320999B1 (no) | 1996-06-11 | 1998-12-11 | Anordning for transdermal administrering av 2 aktive ingredienser i separate seksjoner og dens fremstillingsprosess. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0904086B1 (es) |
JP (1) | JP2000511921A (es) |
CN (1) | CN1119150C (es) |
AR (1) | AR008229A1 (es) |
AT (1) | ATE284215T1 (es) |
AU (1) | AU739141B2 (es) |
BR (1) | BR9715082A (es) |
CA (1) | CA2257913A1 (es) |
CZ (1) | CZ295350B6 (es) |
DE (1) | DE69731883T2 (es) |
ES (1) | ES2235236T3 (es) |
FR (1) | FR2749514B1 (es) |
NO (1) | NO320999B1 (es) |
PL (1) | PL189361B1 (es) |
RU (1) | RU2209090C2 (es) |
TR (1) | TR199802577T2 (es) |
TW (1) | TWI228999B (es) |
WO (1) | WO1997047305A1 (es) |
ZA (1) | ZA975160B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200306196A (en) * | 2002-04-03 | 2003-11-16 | Wyeth Corp | Hormone replacement therapy |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
WO2006041907A2 (en) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Transdermal delivery of estradiol |
DE102005034498A1 (de) * | 2005-07-20 | 2007-01-25 | Grünenthal GmbH | Orale Kontrazeption mit Trimegeston |
CA2635575A1 (en) | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
US10821297B2 (en) * | 2016-09-30 | 2020-11-03 | Johnson & Johnson Consumer Inc. | Kit and method for topical delivery of benefits |
JP6982960B2 (ja) * | 2017-02-07 | 2021-12-17 | リンテック株式会社 | 包材および包装体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2430953A1 (fr) * | 1978-07-13 | 1980-02-08 | Roussel Uclaf | Nouveaux derives 3,20-dioxo 4,9-diene 21-hydroxyle, leur procede de preparation et leur application comme medicaments |
DE3714140A1 (de) * | 1987-04-28 | 1988-11-10 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut |
US5788983A (en) * | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
-
1996
- 1996-06-11 FR FR9607209A patent/FR2749514B1/fr not_active Expired - Fee Related
-
1997
- 1997-06-10 CN CN97197162A patent/CN1119150C/zh not_active Expired - Fee Related
- 1997-06-10 EP EP97928318A patent/EP0904086B1/fr not_active Expired - Lifetime
- 1997-06-10 TR TR1998/02577T patent/TR199802577T2/xx unknown
- 1997-06-10 BR BR9715082-7A patent/BR9715082A/pt not_active IP Right Cessation
- 1997-06-10 AU AU32661/97A patent/AU739141B2/en not_active Ceased
- 1997-06-10 DE DE69731883T patent/DE69731883T2/de not_active Expired - Fee Related
- 1997-06-10 PL PL97330597A patent/PL189361B1/pl not_active IP Right Cessation
- 1997-06-10 CA CA002257913A patent/CA2257913A1/fr not_active Abandoned
- 1997-06-10 AT AT97928318T patent/ATE284215T1/de not_active IP Right Cessation
- 1997-06-10 JP JP10501289A patent/JP2000511921A/ja not_active Abandoned
- 1997-06-10 WO PCT/FR1997/001024 patent/WO1997047305A1/fr active IP Right Grant
- 1997-06-10 CZ CZ19984108A patent/CZ295350B6/cs not_active IP Right Cessation
- 1997-06-10 RU RU99100390/14A patent/RU2209090C2/ru not_active IP Right Cessation
- 1997-06-10 ES ES97928318T patent/ES2235236T3/es not_active Expired - Lifetime
- 1997-06-10 AR ARP970102528A patent/AR008229A1/es active IP Right Grant
- 1997-06-11 ZA ZA9705160A patent/ZA975160B/xx unknown
- 1997-06-16 TW TW086108355A patent/TWI228999B/zh not_active IP Right Cessation
-
1998
- 1998-12-11 NO NO19985807A patent/NO320999B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
DE69731883T2 (de) | 2005-12-22 |
NO985807D0 (no) | 1998-12-11 |
CZ410898A3 (cs) | 1999-09-15 |
WO1997047305A1 (fr) | 1997-12-18 |
CA2257913A1 (fr) | 1997-12-18 |
EP0904086B1 (fr) | 2004-12-08 |
AR008229A1 (es) | 1999-12-29 |
BR9715082A (pt) | 2003-07-15 |
CN1119150C (zh) | 2003-08-27 |
ZA975160B (en) | 1998-06-11 |
EP0904086A1 (fr) | 1999-03-31 |
TWI228999B (en) | 2005-03-11 |
TR199802577T2 (xx) | 1999-03-22 |
FR2749514B1 (fr) | 1998-08-07 |
AU739141B2 (en) | 2001-10-04 |
FR2749514A1 (fr) | 1997-12-12 |
ES2235236T3 (es) | 2005-07-01 |
PL189361B1 (pl) | 2005-07-29 |
CZ295350B6 (cs) | 2005-07-13 |
ATE284215T1 (de) | 2004-12-15 |
NO985807L (no) | 1999-02-10 |
CN1227492A (zh) | 1999-09-01 |
PL330597A1 (en) | 1999-05-24 |
RU2209090C2 (ru) | 2003-07-27 |
DE69731883D1 (de) | 2005-01-13 |
JP2000511921A (ja) | 2000-09-12 |
AU3266197A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2154455C2 (ru) | Чрескожные терапевтические системы, содержащие половые стероиды | |
US9005653B2 (en) | Transdermal delivery of hormones with low concentration of penetration enhancers | |
RU2177311C2 (ru) | Трансдермальный пластырь для введения 17-деацетилноргестимата отдельно или в сочетании с эстрогеном | |
DK171138B1 (da) | Transdermal absorptionsdosisenhed til behandling af postmenopausesyndrom | |
MXPA94003365A (es) | Sistema terapeutico transdermico conteniendo estradiol. | |
SK79197A3 (en) | Transdermal system for the simultaneous delivery of a number of active principles | |
JPH04504109A (ja) | エストロゲン/プロゲスチン経皮投与ユニット,そのシステムとプロセス | |
JP2005528356A (ja) | 改善された粘着力を有する酢酸ビニル−ビニルピロリドン共重合体に基づく活性物質貯留部を備えた、ホルモン含有経皮治療システム | |
IL176112A (en) | Skin-containing preparation through the stomach containing gastodone and carrier, a medical system for the administration through the skin containing gastodon and a kit | |
NO320999B1 (no) | Anordning for transdermal administrering av 2 aktive ingredienser i separate seksjoner og dens fremstillingsprosess. | |
EP1541137A2 (en) | Transdermal delivery system of hormones without penetration enhancers | |
RU2204417C2 (ru) | Новые устройства, предназначенные для чрескожного введения тримегестона | |
JPH09508911A (ja) | デソゲストレルを含有する経皮適用剤 | |
KR100496109B1 (ko) | 개별격실에2종의활성성분을함유하는경피시스템,그의제조방법및의약으로서의그의용도 | |
MXPA98010572A (es) | Sistemas transdermicos que incluyen dos principios activos en compartimientos separados, su procedimiento de preparacion y su aplicacion como medicamentos | |
KR20010029770A (ko) | 에스트로겐 작용물질-길항물질을 포함하는 경피 투여용조성물 | |
KR20000016540A (ko) | 트리메게스톤 경피 투여용 신규 장치 |